Quantcast
Last updated on April 21, 2014 at 5:04 EDT

Latest Dronedarone Stories

2013-09-04 16:27:45

BRIDGEWATER, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013 /PRNewswire/ -- Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive...

2013-09-03 12:26:34

-- GARFIELD Registry presentations at ESC CONGRESS 2013 provide outcomes data on real-world treatment patterns of at-risk AF populations -- AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- One-year outcomes data from the first cohort of the Global Anticoagulant Registry in the FIELD (GARFIELD), an innovative, independent academic research initiative, provide insights into the elevated stroke risk among subpopulations of patients with atrial fibrillation (AF). The findings, from eight abstracts...

2012-04-26 23:01:58

On April 15th 2012, the Financial Times reported that Sanofi´s drug Multaq lost reimbursement in France and faced new restrictions in other countries. Multaq (Dronedarone) is a drug manufactured by Sanofi and used by patients who had recently experienced heart issues like atrial fibrillation (a type of abnormal heart rhythm) or atrial flutters. It was approved by the FDA in 2009. In January 2011, the FDA issued a warning about cases of rare, but severe liver injury, including two cases...

2012-02-28 10:35:00

An irregular heartbeat – atrial fibrillation – is a strong predictor of cognitive decline and the loss of independence in daily activities in older people at risk of cardiovascular disease, according to a study in CMAJ (Canadian Medical Association Journal). Researchers sought to understand whether there was an association between an irregular heartbeat and the loss of mental and physical functions in people at risk of cardiovascular disease. They looked at data from two...

2011-11-14 08:30:00

RIDGEFIELD, Conn., Nov. 14, 2011 /PRNewswire/ -- A new retrospective subanalysis of the RE-LY® trial found Pradaxa® (dabigatran etexilate mesylate) capsules 150mg twice daily reduced the risk of stroke and systemic embolism compared to warfarin in patients with non-valvular atrial fibrillation (NVAF) irrespective of the presence of symptomatic heart failure (sHF), with no significant interaction for major bleeding events.(1) The results were presented...

2011-06-27 15:00:00

LA JOLLA, Calif., June 27, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR® for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal. "I am very encouraged that our approach of restoring a critical enzyme...

2011-05-23 09:00:00

SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy. "We are pleased to present data from the...

2011-05-04 19:26:22

Lead investigator available at HeartRhythm 2011 to discuss data that underscore the growing impact of AFib on US health care costs and resources Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation (AFib), the most common form of cardiac arrhythmia. Each study evaluates these costs and updates a growing body of evidence suggesting that the true costs of AFib are complex and may not yet be fully understood. The patient populations studied...

2011-02-18 08:08:51

(Ivanhoe Newswire) "“ Use of an implanted device to monitor the condition of heart failure patients reduces the rate of hospitalization by 39 percent, according to this study. These findings also indicate a low device failure rate, suggesting that the devices can be safely used and therefore significantly reduce the cost of care. The implanted device works by measuring the pressures within the pulmonary arteries (those connecting the heart to the lungs). In the study, patients with...

2010-12-20 19:29:07

American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines Statement Highlights:     * Strict heart rate control in atrial fibrillation patients is not beneficial over lenient control.    * The antiplatelet drug clopidogrel, plus aspirin, might be considered to reduce the risk of major vascular events, including stroke in patients who are poor candidates for the anticoagulant drug warfarin.    * Catheter ablation is...